Role of hypothalamic-pituitary-adrenal-axis in affective disorders: Anti-depressant and anxiolytic activity of partial 5-HT1A agonist in adrenalectomised rats

Indian Journal of Psychological Medicine

Volumn 35, Issue 3, 2013, Pages 290-298

  Gupta, Deepali ^a   Radhakrishnan, Mahesh ^a   Bhatt, Shvetank ^a   Kurhe, Yeshwant ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT 1A partial agonist; adrenalectomy; depression

Indexed keywords

EID: 84886243865     PISSN: 02537176     EISSN: 09751564     Source Type: Journal    
DOI: 10.4103/0253-7176.119501     Document Type: Article

References (37)

1. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J. Long-term outcome of episodes of major depression. Clinical and public health significance. JAMA 1984;252:788-92.
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965;122:509-22.
3. Hensler JG. Serotonergic modulation of the limbic system. Neurosci Biobehav Rev 2006;30:203-14.
4. Seo D, Patrick CJ, Kennealy PJ. Role of Serotonin and Dopamine System Interactions in the Neurobiology of Impulsive Aggression and its Comorbidity with other Clinical Disorders. Aggress Violent Behav 2008;13:383-395.
5. Rajkumar R, Mahesh R. Assessing the neuronal serotonergic target-based antidepressant stratagem: Impact of in vivo interaction studies and knockout models. Curr Neuropharmacol 2008;6:215-34.
6. Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target? J Psychopharmacol 2010;24:455-69.
7. Dunbar GC, Judge R. Longterm evaluation of paroxetine, clomipramine and placebo in panic disorder. Eur Neuropsychopharmacol 1995;5:361-2.
8. Uhlenhuth EH, Balter MB, Ban TA, Yang K. International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications: I I . Pharmacotherapy of anxiety disorders. J Affect Disord 1995;35:153-62.
9. Allsopp LF, Cooper GL, Poole PH. Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Curr Med Res Opin 1984;9:64-70.
10. Lôo H, Saiz-Ruiz J, Costa e Silva JACE, Ansseau M, Herrington R, Vaz-Serra A, et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J Affect Disord 1999;56:109-18.
11. Piñeyro G, Blier P. Autoregulation of serotonin neurons: Role in antidepressant drug action. Pharmacol Rev 1999;51:533-91.
12. Redmond AP, Leonard BE. An evaluation of the role of noradrenergic system in the neurobiology of depression: A review. Hum Psychopharmacol Clin Exp 1997;12:407-30.
13. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med 1986;314:1329-35.
14. Stefanski R, Palejko W, Kostowski W, Plaznik A. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology 1992;31:1251-8.
15. Bodnoff SR, Suranyi-Cadotte B, Quirion R, Meaney MJ. A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology (Berl) 1989;97:277-9.
16. Przegalinski E, Moryl E, Papp M. The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression. Neuropharmacology 1995;34:1305-10.
17. Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979;136:1184-7.
18. Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986;32:114-29.
19. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-Analysis of eight randomized, controlled studies. Neuropsychobiology 1992;25:193-201.
20. Robinson DS, Rickels K, Feighner J, Fabre LF Jr, Gammans RE, Shrotriya RC, et al. Clinical effects of the 5-HT1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10:67S-76.
21. Sato H, Skelin I, Debonnel G, Diksic M. Chronic buspirone treatment normalizes open field behavior in olfactory bulbectomized rats: Assessment with a quantitative autoradiographic evaluation of the 5-HT1A binding sites. Brain Res Bull 2008;75:545-55.
22. Watanabe A, Hasegawa S, Nishi K, Nguyen KQ, Diksic M. Chronic buspirone treatment normalizes regional serotonin synthesis in the olfactory bulbectomized rat brain: An autoradiographic study. Brain Res Bull 2006;69:101-8.
23. Grollman A. Biological assay of adrenal cortical activity. Endocrinol 1941;29:855-61.
24. Kelly JP, Wrynn AS, Leonard BE. The olfactory bulbectomized rat as a model of depression: An update. Pharmacol Ther 1997;74:299-316.
25. Muscat R, Papp M, Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology (Berl) 1992;109:433-8.
26. Shibata S, Nakanishi H, Watanabe S, Ueki S. Effects of chronic administration of antidepressants on mouse-killing behavior (muricide) in olfactory bulbectomized rats. Pharmacol Biochem Behav 1984;21:225-30.
27. Yamada K, Iida R, Miyamoto Y, Saito K, Sekikawa K, Seishima M, et al. Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-Alpha gene: Implications for emotional behavior. J Neuroimmunol 2000;111:131-8.
28. Aguilera G. Corticotropin releasing hormone, receptor regulation and the stress response. Trends Endocrinol Metab 1998;9:329-36.
29. Ts igos C, Chrousos GP. Phys iology o f the hypothalamic-pituitary- Adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metab Clin North Am 1994;23:451-66.
30. Parker GA, Valerio MG. Accessory adrenocortical tissue, rat. Endocrine Sys (Berl) 1983;16-7.
31. American Psychiatric Association. Mood Disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. text revision. Washington DC: American Psychiatric Association; 2000; pp.345-70.
32. Rex A, Voigt JP, Voits M, Fink H. Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav 1998;59:677-83.
33. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review. Eur J Pharmacol 2003;463:3-33.
34. Verma P, Hellemans KG, Choi FY, Yu W, Weinberg J. Circadian phase and sex effects on depressive/anxiety-like behaviors and HPA axis responses to acute stress. Physiol Behav 2010;99:276-85.
35. Taylor DP, Hyslop DK, Riblet LA. Buspirone: Model for anxioselective drug action. Soc Neurosci Abstr 1980;6:791.
36. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 1996;54:21-30.
37. Griebel G, Rodgers RJ, Perrault G, Sanger DJ. Risk assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol Biochem Behav 1997;57:817-27.